-
Simvastatin-d11，MK 733-d11「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Simvastatin-d11 is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Simvastatin-d11 相关抗体:HMGCS2 AntibodyERK1/2 AntibodyE-Cadherin Antibody (YA470)Fatty Acid Synthase Antibody (YA766)DYKDDDDK Tag (FLAG) AntibodyGAPDH AntibodyGFP Antibodyp53 Antibody (YA250)RUNX2 AntibodyFerritin Heavy Chain AntibodyCOX2 AntibodyCtip2 AntibodyCyclin D1 Antibody (YA485)Cytochrome C Antibodyc-Myc AntibodyCyclin E1 AntibodyAIF Antibody (YA636)ALIX AntibodyCNPase AntibodyCortactin AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCyclin A2 AntibodyCyclin B1 Antibody (YA486)DR5 AntibodyDrosha AntibodyE-Cadherin Antibody (YA778)EEA1 AntibodyEpCAM Antibody (YA772)Fatty Acid Synthase Antibody分子量：429.63Formula：C25H27D11O5CAS 号：1002347-74-1非标记 CAS：79902-63-9中文名称：辛伐他汀 d11运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (530 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetic
-
Cilostazol-d4，西洛他唑-d4; OPC-13013-d4「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Cilostazol-d4 is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Cilostazol-d4 相关抗体:PDE1B Antibody (YA1553)PDE4B Antibody (YA2932)PDE2A Antibody (YA2989)PDE4D Antibody (YA1714)分子量：373.49Formula：C20H23D4N5O2CAS 号：1215541-47-1非标记 CAS：73963-72-1中文名称：西洛他唑-d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (528 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61(25):PL 383-9. [Content Brief][3]. Schr?r K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S14-9. [Content Brief][4]. Saito S, et al. Cilos
-
Tranylcypromine-d5 hydrochloride，SKF 385-d5 hydrochloride「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Tranylcypromine-d5 (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].IC50 & Target：KDM1/LSD1分子量：174.68Formula：C9H7D5ClNCAS 号：107077-98-5非标记 CAS：1986-47-6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (530 KB)产品使用指南 (1538 KB)参考文献[1]. Caraci F, et al. Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against Aβ(1-42)-induced toxicity. Eur J Pharmacol. 2015 Oct 5;764:256-263. [Content Brief][2]. Sun Q, et al. Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Reprod Biol Endocrinol. 2016 Apr 9;14:17. [Content Brief]
-
Amprenavir-d4-1，安瑞那韦-d4; VX-478-d4-1「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Amprenavir-d4-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Amprenavir-d4-1 相关抗体:CD4 AntibodyTARBP2 Antibody (YA1433)SAMHD1 Antibody (YA1542)SV40 T Antigen Antibody (YA3256)CLEC12A Antibody (YA1419)Tat SF1 Antibody (YA2886)分子量：509.65Formula：C25H31D4N3O6SCAS 号：2738376-78-6非标记 CAS：161814-49-9中文名称：安瑞那韦-d4-1运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Sadler BM, Stein DS. Clinical pharmacology and pharmacokinetics of amprenavir. Ann Pharmacother. 2002 Jan;36(1):102-18. [Content Brief][3]. Esposito V, Verdina A, Manente L, Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol. 2013 Mar;228(3):64
-
Flecainide-d4 acetate，R-818-d4「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Flecainide-d4 (acetate) is the deuterium labeled Flecainide acetate. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Flecainide-d4 acetate 相关抗体:xCT Antibody (YA006)xCT Antibody (YA652)Alpha-ENaC AntibodyCRMP2 Antibody (YA3370)SLC12A1 Antibody (YA1403)CRMP1 Antibody (YA1941)CRMP5 Antibody (YA2497)CRMP3 Antibody (YA2563)CRMP4 Antibody (YA2777)分子量：478.42Formula：C19H20D4F6N2O5CAS 号：1276197-21-7非标记 CAS：54143-56-5性状：固体颜色：White to off-white中文名称：醋酸氟卡尼 d4 (醋酸盐)运输条件：Room temperature in continental US; may vary elsewhere.储存方式：4°C, sealed storage, away from moisture*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Urocanic acid-13C3，尿刊酸-13C3「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Urocanic acid-13C3 is the 13C labeled Urocanic acid[1]. Urocanic acid, produced in the upper layers of mammalian skin, is a major absorber of ultraviolet radiation (UVR)[2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Urocanic acid-13C3 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：141.10Formula：C313C3H6N2O2CAS 号：1173097-34-1非标记 CAS：104-98-3中文名称：尿刊酸-13C3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (526 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Im
-
Tazarotenic acid-d6，AGN 190299-d6「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Tazarotenic acid-d6 is deuterium labeled Tazarotenic acid. Tazarotenic acid is the metabolite of Tazarotene. Tazarotenic acid binding to retinoic acid receptors (RARs) is the probable molecular target of retinoid action. Tazarotenic acid has the potential for the research of warty dyskeratoma[1][2][3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Tazarotenic acid-d6 相关抗体:FMO3 Antibody (YA1992)分子量：329.45Formula：C19H11D6NO2SCAS 号：1794760-38-5非标记 CAS：118292-41-4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Chandraratna RA. Tazarotene--first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996;135 Suppl 49:18-25. [Content Brief][3]. Hsyu PH, et al. Pharmacokinetics of a novel retinoid AGN 190168 and its metabolite AGN 190299 after intravenous administration of AGN 190168 to rats. Biopharm Drug Dispos. 1994;15(5):347-357. [Content
-
5-OxoETE-d7，5-KETE-d7「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：5-OxoETE-d7 is the deuterium labeled 5-OxoETE[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：325.49Formula：C20H23D7O3CAS 号：1881277-29-7非标记 CAS：106154-18-1运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (517 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine-d70，DSPE-d70「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine-d70 is deuterium labeled 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine. 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine (DSPE) is a phosphoethanolamine (PE) lipid that can be used in the synthesis体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[2].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine-d70 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：818.50Formula：C41H12D70NO8PCAS 号：326495-43-6非标记 CAS：1069-79-0性状：固体颜色：White to off-white运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 yearsIn solvent：-80°C：6 mon
-
WNK-IN-11-d3「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：WNK-IN-11-d3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d3 is effective at regulating cardiovascular homeostasis[1].IC50 & Target：WNK[1]体内研究(In Vivo)WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability[1].WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice[1].WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg[1].WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Animal Model:Sprague−Dawley rats[1]Dosage:1.5 mg/kg Administration:P.o.Result:Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.Animal Model:FVB mice[1]Dosage:30 mg/kg Administration:P.o.Result:Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.Animal Model:FVB mice[1]Dosage:0~100 mg/kg Administration:P.o.Result:Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.分子量：465.41Formula：C21H18D3Cl2N5OSCAS 号：2123483-49-6非标记 CAS：2123489-30-3性状：固体颜色：Off-white to light yell
-
Fingolimod-d4，FTY720 free based-d4「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Fingolimod-d4 相关抗体:PAK2 Antibody (YA695)PAK1 Antibody (YA1363)KPNA2 Antibody (YA1415)Phospho-PAK1/2/3 (Ser144/Ser141/Ser154) Antibody (YA1530)SCARB1 Antibody (YA1908)EDG3 Antibody (YA2359)Involucrin Antibody (YA2488)JAB1 Antibody (YA3159)Myelin Basic Protein Antibody (YA3271)Phospho-PAK4/5/6 (Ser474/Ser560/Ser602) Antibody (YA3333)S1PR4 AntibodyJMJD6 Antibody (YA1064)Scavenging Receptor SR-BI Antibody (YA1160)EDG1 Antibody (YA1239)LILRB1 Antibody (YA1261)PAK3 Antibody (YA1367)KSR1 Antibody (YA1391)PKN1 Antibody (YA1664)Lipoamide Dehydrogenase Antibody (YA1694)Intra Acrosomal Protein Antibody (YA1856)Lipin 1 Antibody (YA1909)Lactoferrin Antibody (YA2274)LCAT Antibody (YA2864)PKN2 Antibody (YA2890)ITPA Antibody (YA3104)L1CAM Antibody (YA3149)LAT Antibody (YA3161)Myelin Protein Zero Antibody (YA3278)EDG2 Antibody (YA3375)分子量：311.50Formula：C19H29D4NO2CAS 号：1346747-38-3非标记 CAS：162359-55-9性状：固体颜色：White
-
(S-Rivastigmine-d6 tartrate，酒石酸卡巴拉汀 D6「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：(S)-Rivastigmine-d6 (tartrate) is the deuterium labeled (S)-Rivastigmine, which is an cholinesterase inhibitor.分子量：406.46Formula：C18H22D6N2O8CAS 号：194930-00-2性状：固体颜色：White to off-white中文名称：酒石酸卡巴拉汀 d6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：-20°C, sealed storage, away from moisture*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
N-Arachidonyldopamine-d8「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：N-Arachidonyldopamine-d8 is the deuterium labeled N-Arachidonyldopamine[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.N-Arachidonyldopamine-d8 相关抗体:TRPM8 Antibody (YA1609)Phospho-Cannabinoid Receptor I (Ser316) Antibody (YA2350)TRPM7 Antibody (YA2391)TrpC1 Antibody (YA1814)分子量：447.68Formula：C28H33D8NO3CAS 号：1159908-42-5非标记 CAS：199875-69-9运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (513 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
Trametinib-13C,d3，曲美替尼-13C,d3; GSK1120212-13C,d3; JTP-74057-13C,d3「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Trametinib-13C,d3 is the 13C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[88].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Trametinib-13C,d3 相关抗体:MEK1/2 AntibodyERK1/2 AntibodyE-Cadherin Antibody (YA470)Fatty Acid Synthase Antibody (YA766)DYKDDDDK Tag (FLAG) AntibodyGAPDH AntibodyGFP Antibodyp53 Antibody (YA250)RUNX2 AntibodyFerritin Heavy Chain AntibodyCOX2 AntibodyCtip2 AntibodyCyclin D1 Antibody (YA485)Cytochrome C Antibodyc-Myc AntibodyCyclin E1 AntibodyPhospho-MEK1 (Ser298) AntibodyAIF Antibody (YA636)ALIX AntibodyCNPase AntibodyCortactin AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCyclin A2 AntibodyCyclin B1 Antibody (YA486)DR5 AntibodyDrosha AntibodyE-Cadherin Antibody (YA778)EEA1 AntibodyEpCAM Antibody (YA772)分子量：619.41Formula：C2513CH20D3FIN5O4CAS 号：2712126-59-3非标记 CAS：871700-17-3中文名称：曲美替尼-13C,d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (535
-
Oleoyl Serotonin-d17「同位素标记抑制剂」
作者：德尔塔生物 日期：2025-08-13
生物活性：Oleoyl Serotonin-d17 is the deuterium labeled Oleoyl Serotonin[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Oleoyl Serotonin-d17 相关抗体:TRPM8 Antibody (YA1609)TRPM7 Antibody (YA2391)TrpC1 Antibody (YA1814)分子量：457.77Formula：C28H27D17N2O2CAS 号：2749980-90-1非标记 CAS：1002100-44-8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (515 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
咨询热线
18133906270
德尔塔官方微信